Leucopenia, thrombocytopenia and lymphadenopathy associated with sulphasalazine.
We report a 19-year-old woman with psoriasis who developed a severe allergic reaction within 1 week of commencement of sulphasalazine; her skin becoming erythrodermic with associated lymphadenopathy, leucopenia and thrombocytopenia. Clinical signs and haematological abnormalities rapidly returned to normal on discontinuation of sulphasalazine. It is important to monitor carefully haematological indices in the early stages of treatment with this drug.
McKenna
K E
KE
Department of Dermatology, Royal Victoria Hospitals Trust, Belfast, N. Ireland, UK.
Burrows
D
D
D000328:Adult; D005260:Female; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced*; D008206:Lymphatic Diseases / Q000139:chemically induced*; D011565:Psoriasis / Q000188:drug therapy; D012460:Sulfasalazine / Q000009:adverse effects* / Q000627:therapeutic use; D013921:Thrombocytopenia / Q000139:chemically induced*
D012460:Sulfasalazine